Nasdaq dbtx.

5 analysts have issued 1 year price targets for Decibel Therapeutics' shares. Their DBTX share price targets range from $2.00 to $23.00. On average, they predict the company's share price to reach $8.45 in the next twelve months. This suggests a possible upside of 72.1% from the stock's current price. View analysts price targets for DBTX or ...BOSTON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...The average twelve-month price prediction for Decibel Therapeutics is $8.45 with a high price target of $23.00 and a low price target of $2.00. Learn more on DBTX's analyst rating history. Do Wall Street analysts like Decibel Therapeutics more than its competitors?BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...Oct 17, 2022 · BOSTON, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...

DBTX Latest Real Time Trades. Select time range to see more trades: Last 100 Trades. NLS Time (ET) NLS Price. NLS Share Volume. 16:00:04. $ 4.33. 42.Based on analysts offering 12 month price targets for DBTX in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .

Director. 02/17/2021. Acquisition (Non Open Market) Indirect. 3,278,526. 2,732,106. Back to DBTX Overview. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the ...

BOSTON, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage company developing treatments to restore and improve hearing and balance, presented preclinical data ...Jun 29, 2023 · A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. As at March 2023, Decibel Therapeutics had cash of US$88m and no debt ... NASDAQ, #2023-527, (UPDATED: Merger closed) Information Regarding the Tender Offer of Decibel Therapeutics, Inc. (DBTX). Sep 18, 2023, NASDAQ, #2023-526, ( ...About Nasdaq Nasdaq (Nasdaq: NDAQ) is a global technology company serving the capital markets and other industries. Our diverse offering of data, analytics, software, and services enables clients ...... DBTX(DBTX)股票股价,股票实时行情,新闻,财报,美股实时交易数据,研究报告,评级,财务指标分析等与DBTX(DBTX) ... DBTX NASDAQ:DBTX Decibel Therapeutics. 添加自选 在APP中查看.

BOSTON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...

Decibel Therapeutics, Inc. (Nasdaq: DBTX), relating to its proposed acquisition by Regeneron Pharmaceuticals, Inc. Under the terms of the tender offer, DBTX shareholders will receive $4.00 in cash ...

BOSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...The Decibel Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.Feb 9, 2022 · BOSTON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ... (Nasdaq: ZEUS). He is also Chair and a director of University Hospitals Health ... (Nasdaq: DBTX) and a former member and Vice-Chairwoman of the Supervisory ...BOSTON, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...... DBTX DECIBEL THERAPEUTICS. US$ 4.91. 0.00 0.00. 0. 25.13M. US$ 123.390M. Follow · NASDAQ ... NASDAQ: ROIV. Oral brepocitinib failed to meet its primary endpoint ...Find the latest historical data for Decibel Therapeutics, Inc. Common Stock (DBTX) at Nasdaq.com. Decibel Therapeutics, Inc. Common Stock (DBTX) Historical Data | Nasdaq Skip to main...

BOSTON, June 28, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...Find the latest SEC Filings data for Decibel Therapeutics, Inc. Common Stock (DBTX) at Nasdaq.com.BOSTON, March 30, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...BOSTON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...

See the latest Decibel Therapeutics Inc Ordinary Shares stock price (NASDAQ:DBTX), related news, valuation, dividends and more to help you make your investing decisions.Decibel intends to initiate the Phase 1/2 clinical trial of DB-OTO in the first half of 2023. BOSTON, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage ...

According to NASDAQ, as of May 2014, the highest NASDAQ closing ever was achieved on March 9, 2000, when the market closed at a record 5046.86. USA Today reports that the highest closing achieved by NASDAQ since was a 4007.09 closing on Nov...BOSTON, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...BOSTON, June 28, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...TARRYTOWN, N.Y. and BOSTON, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Decibel Therapeutics, Inc. (NASDAQ: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today …BOSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...Decibel Therapeutics, Inc. (Nasdaq: DBTX), relating to its proposed acquisition by Regeneron Pharmaceuticals, Inc. Under the terms of the tender offer, DBTX shareholders will receive $4.00 in cash ...Decibel Therapeutics, Inc. (Nasdaq - DBTX) Under the terms of the Merger Agreement, Decibel will be acquired by Regeneron Pharmaceuticals, Inc. (Nasdaq - REGN). Decibel shareholders will receive ...Oct 17, 2022 · BOSTON, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...

BOSTON, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...

IPO lockups expire on Signify Health (SGFY), Viant Technology , Apria (APR), Bumble , Bioventus , LoanDepot , Decibel Therapeutics (NASDAQ:DBTX), NexImmune and Talis Biomedical .

Decibel Therapeutics, Inc. (Nasdaq: DBTX), relating to its proposed acquisition by Regeneron Pharmaceuticals, Inc. Under the terms of the tender offer, DBTX shareholders will receive $4.00 in cash ...Nasdaq News: This is the News-site for the company Nasdaq on Markets Insider Indices Commodities Currencies StocksEmployees: 1,693. Coupa Software is one of the 15 fastest-growing software companies. It is a business management software platform. Coupa is a cloud-based platform that analyzes the transactional ...Decibel Therapeutics, Inc. (NASDAQ:DBTX) rose 13.5% to close at $4.88. Decibel Therapeutics recently reported top-line results from an interim analysis of its ongoing Phase 1b clinical trial of DB ...Find the latest SEC Filings data for Decibel Therapeutics, Inc. Common Stock (DBTX) at Nasdaq.com. Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has extended the research term of its collaboration with Decibel Therapeutics Inc (NASDAQ: DBTX) to discover and develop gene therapies for hearing loss.Nov 22, 2021 · Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has extended the research term of its collaboration with Decibel Therapeutics Inc (NASDAQ: DBTX) to discover and develop gene therapies for hearing loss. (DBTX) reported a total revenue of $12.5 million in the first quarter of 2022 ... NASDAQ · NYSE · Blog. Need Help? [email protected]. Create your mobile categories ...Find the latest news headlines from Dropbox, Inc. Class A Common Stock (DBX) at Nasdaq.com.BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...Nasdaq Listed 1 High Technical Attribute Add to Watchlist Add to Portfolio DBTX DBTX FINANCIALS DBTX Financials Income Statement Balance Sheet Cash …Decibel Therapeutics, Inc. (Nasdaq: DBTX), relating to its proposed acquisition by Regeneron Pharmaceuticals, Inc. Under the terms of the tender offer, DBTX shareholders will receive $4.00 in cash ...

Cash Position: As of March 31, 2023, cash, cash equivalents and available-for-sale securities were $87.9 million, compared to $104.6 million as of December 31, 2022. Research and Development ...Find the latest historical data for Decibel Therapeutics, Inc. Common Stock (DBTX) at Nasdaq.com. Decibel Therapeutics, Inc. Common Stock (DBTX) Historical Data | Nasdaq Skip to main...BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...Instagram:https://instagram. panw share priceamzmstock analysis programhow does groundfloor work Find the latest Earnings Report Date for Decibel Therapeutics, Inc. Common Stock (DBTX) at Nasdaq.com.25-Sept-2023 ... Regeneron Pharmaceuticals, Inc.(NASDAQ:REGN): Growing adoption of AI technologies by biopharmaceutical companies and growing foothold of ... buy wwe stockreliable forex brokers Jan 24, 2023 · Decibel intends to initiate the Phase 1/2 clinical trial of DB-OTO in the first half of 2023. BOSTON, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage ... Decibel Therapeutics, Inc. Common Stock (DBTX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. ameritrade options trading BOSTON, March 22, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and... DBTX : 4.33 …BOSTON, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage company developing treatments to restore and improve hearing and balance, presented preclinical data ...Company profile page for Decibel Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information